NCT05862194 2023-08-22Retrospective, External Comparator Study of Lazertinib as the 2nd-Line Treatment in Patients With EGFR Mutation+ NSCLCYuhan CorporationCompleted534 enrolled
NCT05716672 2023-02-08Impact of Lazertinib Dose Modification on Effectiveness and SafetyPusan National University HospitalUnknown200 enrolled
NCT05377788 2022-05-19Lazertinib Real-world Observational Study of in Pre-treated EGFR T790M Mutant With Advanced Non-small Cell Lung CancerSamsung Medical CenterUnknown900 enrolled